Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Ltd (OKYO) is a clinical-stage biopharmaceutical company pioneering novel therapies for ocular inflammatory conditions and neuropathic pain. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory developments, and strategic partnerships.
Investors and researchers will find timely updates on OKYO's lead candidate OK-101, a patented chemerin analog targeting dry eye disease and corneal neuropathic pain. All content is sourced directly from company filings and press releases to ensure accuracy.
The news archive includes updates on: Phase 2 clinical trial progress, intellectual property milestones, research collaborations, and regulatory pathway developments. Content is organized chronologically for tracking therapeutic advancement timelines.
Bookmark this page for streamlined access to OKYO's latest scientific and corporate developments. Check regularly for updates on ocular therapeutic innovations with potential to address unmet medical needs in global markets.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has announced the activation of its first clinical trial site in the U.S. for a phase 2 study of its ophthalmic solution, OK-101, aimed at treating dry eye disease. The trial is a multi-center, randomized, double-blinded, placebo-controlled study designed to evaluate the efficacy and safety of OK-101. The first patient visit is anticipated within two weeks. CEO Gary S. Jacob emphasized the company's commitment to advancing OK-101’s development, noting that dry eye disease affects approximately 700 million people globally. OK-101 is a novel long-acting drug candidate developed to alleviate inflammation and pain associated with dry eye conditions.
OKYO Pharma Ltd. (NASDAQ:OKYO) is advancing towards its first phase 2 trial of the drug OK-101, with plans to release efficacy data by year-end 2023. To facilitate this, the company announced a private stock placement aimed at raising $5.7 million through the issuance of over 12 million shares (American Depositary Shares and Ordinary Shares). Notably, senior management has opted to take shares as compensation for deferred wages, showcasing their confidence in the company’s future. The phase 2 trial, set to commence in Q2 2023, focuses on treating chronic dry eye disease, a significant market valued at over $5 billion in 2019. The company collaborates with contract research organizations for efficient research execution.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
